Chemotherapy remains the major treatment option for castration-resistant prostate cancer
(CRPC) and limited cytotoxic options are available. Inherent chemotherapy resistance …

Abstract Purpose: Interleukin-6 (IL-6) facilitates cancer cell survival via pleotrophic effects.
We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy …

Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC).
However, adverse side effects and problems associated with chemo-resistance limit its …

Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment
resistance when overexpressed. This study tested custirsen, a CLU inhibitor, in patients with …

PURPOSE: Castration-refractory prostate cancer remains a therapeutic challenge even after
introduction of docetaxel as first-line treatment. Castration-refractory prostate cancer cannot …

ABSTRACT DNA-damaging agents cause a multifaceted cellular stress response. Cells set
in motion either repair mechanisms or programmed cell death pathways, depending on the …

Prostate cancer (PCa) stem/progenitor cells are known to have higher chemoresistance than
non-stem/progenitor cells, but the underlying molecular mechanism remains unclear. We …

The membrane protein caveolin-1 (Cav1) recently emerged as a novel oncogene involved
in prostate cancer progression with opposed regulation in epithelial tumor cells and the …

Background Treatment options remain limited for patients with castration-resistant prostate
cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B …

There is a growing number of new therapies targeting different pathways that will
revolutionize patient management strategies in castration-resistant prostate cancer (CRPC) …